Blood cell-derived transplants at 40
February, 2026 is the 40th anniversary of the 1st publication of rapid recovery of bone marrow function after high-dose chemotherapy and infusion of an autologous blood- rather than a bone-marrow-derived graft. The recipient, a man with advanced Burkitt lymphoma, is in remission and alive. In the ne...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | Article (Journal) |
| Lenguaje: | inglés |
| Publicado: |
2026
|
| In: |
Bone marrow transplantation
Year: 2026, Volumen: 61, Número: 6, Pages: 663-667 |
| ISSN: | 1476-5365 |
| DOI: | 10.1038/s41409-026-02865-6 |
| Acceso en línea: | Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s41409-026-02865-6 Verlag, kostenfrei, Volltext: https://www.nature.com/articles/s41409-026-02865-6 
|
| Notas de Autor: | Anthony D. Ho, Peter Dreger, Christopher Juttner and Robert Peter Gale |
| Sumario: | February, 2026 is the 40th anniversary of the 1st publication of rapid recovery of bone marrow function after high-dose chemotherapy and infusion of an autologous blood- rather than a bone-marrow-derived graft. The recipient, a man with advanced Burkitt lymphoma, is in remission and alive. In the next 40 years transplants of blood-derived progenitor cells have become the most common graft for auto- and allotransplants. The rapid hematopoietic recovery after blood cell-derived grafts is associated with fewer short-term complications and better outcomes in many settings compared with bone marrow-derived grafts but may be associated with more graft-versus-host disease (GvHD) after allotransplants. Using blood-derived grafts also reduced costs, enabled the development of cell-based immune therapy and in vitro manipulation of blood-derived cells for gene and chimeric antigen receptor (CAR)-T-cell therapies. |
|---|---|
| Notas: | Online veröffentlicht: 14. April 2026 Gesehen am 17.06.2026 |
| Descripción Física: | Online Resource |
| ISSN: | 1476-5365 |
| DOI: | 10.1038/s41409-026-02865-6 |